A new analysis found that 38% of FDA advisory committee meetings held from 2013 through 2022 included a patient or consumer representative who was actively involved with an advocacy organization funded by pharmaceutical companies.
The finding describes a connection between representatives and funded organizations. It does not establish that representatives personally received industry money, or that the funding changed their advice, committee votes or FDA decisions.
A more direct funding link appeared in 11% of meetings
In 11% of the meetings studied, a representative was affiliated with an organization that received money from the sponsor of the drug under review. For several FDA committees, more than half of meetings included a patient or consumer representative tied to a pharmaceutical-funded advocacy organization.
The paper, by Genevieve P. Kanter and Toni Mankowitz, was published by Health Affairs Scholar on October 7 as an accepted manuscript. Its abstract says the FDA has established conflict-of-interest policies for scientific committee members, but has paid less attention to patient and consumer representatives’ ties to industry-funded advocacy groups. The authors conclude that the relationships were common enough to warrant policy attention.
Why these representatives matter
The FDA says its advisory committees combine scientific experts with members of the public, including consumer and patient representatives. The panels weigh evidence and advise the agency on regulated products and policy questions.
Their recommendations are not binding and do not represent the FDA’s position. The agency considers the advice but makes the final decisions, which is why the study’s findings concern representation and transparency rather than proof of any particular regulatory outcome.
